O'Neal Comprehensive Cancer Center at UAB

The O’Neal Comprehensive Cancer Center at UAB is Alabama’s only cancer center designated by the National Cancer Institute and is a national leader in driving cancer research, advancing new cancer treatments, engaging communities in cancer prevention and early detection initiatives, and training the next generation of cancer physicians and scientists.

 

UAB Hematology Review 2021
09:00

UAB Hematology Review 2021

Sickle Cell Disease in Clinical Practice: Pathophysiology, Mortality, HU Therapy, L-Glutamine, Blood Transfusion, Alloimmunization, Iron Overload

FEATURING Julie Kanter
  • 54 views
  • March 22, 2021
08:14

UAB Hematology Review 2021

New Therapies for Sickle Cell Disease in 2021: Crizanlizumab vs. Placebo, Voxelotor+Placebo, Identifying Appropriate Treatment

FEATURING Julie Kanter
  • 293 views
  • March 22, 2021
  • 1
13:34

UAB Hematology Review 2021

CLL Management in Times of COVID-19: Frontline Acalabrutinib or Ven +/- Obi, Ibrutinib, How to Identify Barriers to Treatment Due to the Ongoing Pandemic?

FEATURING Mayur Narkhede
  • 108 views
  • March 18, 2021
20:13

UAB Hematology Review 2021

Advanced Stage cHL: Considering Frontline, Secondary, and Salvage Treatment Choices and Navigating End of Treatment PET and PET2+ Patients

FEATURING Gaurav Goyal
  • 37 views
  • March 18, 2021
37:07

UAB Hematology Review 2021

Hematopathology Pearls for Clinicians: Danger of “Preliminary Diagnosis”, FNA vs. Core vs. Excisional Biopsy, TAT Factors, Flow Cytometry, NGS

FEATURING Diana Morlote
  • 146 views
  • March 18, 2021
  • 1
18:42

UAB Hematology Review 2021

2021 Updates on the Use of DOACs: Which GI/GU Patients Are Suitable Candidates? Are DOACs Recommended for Obese Patients? Is Rivaroxaban Beneficial for Arterial Thrombosis?

FEATURING Jori May
  • 28 views
  • March 18, 2021
21:42

UAB Hematology Review 2021

Hematologic Manifestations of COVID-19: Thrombosis Mechanisms and Risk, COVID-19 Associated Coagulopathy, Anticoagulation Recommendations, Post-Discharge Prophylaxis

FEATURING Radhika Gangaraju
  • 3,638 views
  • March 18, 2021
  • 16
15:39

UAB Hematology Review 2021

2021 Updates on 2L CML and Beyond: TKIs (Imatinib, Dasatinib/Nilotinib/Bosutinib Continuation, Ponatinib), Omacetaxine, Asciminib, HQP1351

FEATURING Omer Jamy
  • 208 views
  • March 18, 2021
  • 1
24:58

UAB Hematology Review 2021

Interferon for PV: Types, MOA, Effects in MPN, Pegylation of IFN, PEG vs. HU for High-Risk Disease, IFN Alfa-2 vs. HU, PEG-IFN Alfa-2b

FEATURING Pankit Vachhani
  • 360 views
  • March 18, 2021
  • 3
24:01

UAB Hematology Review 2021

2021 UAB Updates on Relapsed DLBCL: Salvage Chemo+ASCT, Len+Rituximab, Bendamustine+Rituximab+Polatuzumab, Tafasitamab+Len, Selinexor, CAR-T

FEATURING Amitkumar Mehta
  • 217 views
  • March 18, 2021
23:44

UAB Hematology Review 2021

Therapeutic Options for R/R MM: Single Agent vs. Doublets vs. Triplets, Summary for Triple Refractory Disease

FEATURING Kelly Godby
  • 313 views
  • March 16, 2021
  • 2
17:39

UAB Hematology Review 2021

Incorporating MoAbs in Frontline Treatment of MM: Assessing the Data From MAIA and GRIFFIN Studies

FEATURING Smith Giri
  • 216 views
  • March 16, 2021
14:06

UAB Hematology Review 2021

Frontline Daratumumab in MM: D-VTd vs. VTd, D-RVd vs. RVd in Transplant-Eligible Disease, Dara-KRd; Dara+/-VMP, Dara+Len/Dex vs. Len Alone in Transplant-Ineligible Disease

FEATURING Susan Bal
  • 97 views
  • March 16, 2021
  • 1
23:19

UAB Hematology Review 2021

Clinical Pearls: 2021 Review of Recently Approved Agents in Hematology

FEATURING Sarah Worth
  • 65 views
  • March 16, 2021
15:48

UAB Hematology Review 2021

UAB 2021 Updates on Frontline MDS: Can We Achieve AUC Decitabine at 5 Days? NTX-301, Aza+Ven, Aza+Magrolimab

FEATURING Kimo Bachiashvili
  • 69 views
  • March 16, 2021